Kato M - Search Results

1

Intestinal first-pass metabolism of CYP3A4 substrates.

Kato M. Kato M. Drug Metab Pharmacokinet. 2008;23(2):87-94. doi: 10.2133/dmpk.23.87. Drug Metab Pharmacokinet. 2008. PMID: 18445987 Review.

2

Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data?

Ito K, Chiba K, Horikawa M, Ishigami M, Mizuno N, Aoki J, Gotoh Y, Iwatsubo T, Kanamitsu S, Kato M, Kawahara I, Niinuma K, Nishino A, Sato N, Tsukamoto Y, Ueda K, Itoh T, Sugiyama Y. Ito K, et al. Among authors: kato m. AAPS PharmSci. 2002;4(4):E25. doi: 10.1208/ps040425. AAPS PharmSci. 2002. PMID: 12645997 Free PMC article.

3

Evaluation of methods for predicting drug-drug interactions by Monte Carlo simulation.

Kato M, Tachibana T, Ito K, Sugiyama Y. Kato M, et al. Drug Metab Pharmacokinet. 2003;18(2):121-7. doi: 10.2133/dmpk.18.121. Drug Metab Pharmacokinet. 2003. PMID: 15618726

4

The intestinal first-pass metabolism of substrates of CYP3A4 and P-glycoprotein-quantitative analysis based on information from the literature.

Kato M, Chiba K, Hisaka A, Ishigami M, Kayama M, Mizuno N, Nagata Y, Takakuwa S, Tsukamoto Y, Ueda K, Kusuhara H, Ito K, Sugiyama Y. Kato M, et al. Drug Metab Pharmacokinet. 2003;18(6):365-72. doi: 10.2133/dmpk.18.365. Drug Metab Pharmacokinet. 2003. PMID: 15618757

5

The quantitative prediction of in vivo enzyme-induction caused by drug exposure from in vitro information on human hepatocytes.

Kato M, Chiba K, Horikawa M, Sugiyama Y. Kato M, et al. Drug Metab Pharmacokinet. 2005 Aug;20(4):236-43. doi: 10.2133/dmpk.20.236. Drug Metab Pharmacokinet. 2005. PMID: 16141603

6

The quantitative prediction of CYP-mediated drug interaction by physiologically based pharmacokinetic modeling.

Kato M, Shitara Y, Sato H, Yoshisue K, Hirano M, Ikeda T, Sugiyama Y. Kato M, et al. Pharm Res. 2008 Aug;25(8):1891-901. doi: 10.1007/s11095-008-9607-2. Epub 2008 May 16. Pharm Res. 2008. PMID: 18483837

7

Prediction of drug-drug interactions based on time-dependent inhibition from high throughput screening of cytochrome P450 3A4 inhibition.

Sekiguchi N, Higashida A, Kato M, Nabuchi Y, Mitsui T, Takanashi K, Aso Y, Ishigai M. Sekiguchi N, et al. Among authors: kato m. Drug Metab Pharmacokinet. 2009;24(6):500-10. doi: 10.2133/dmpk.24.500. Drug Metab Pharmacokinet. 2009. PMID: 20045985

8

Model analysis of the concentration-dependent permeability of P-gp substrates.

Tachibana T, Kitamura S, Kato M, Mitsui T, Shirasaka Y, Yamashita S, Sugiyama Y. Tachibana T, et al. Among authors: kato m. Pharm Res. 2010 Mar;27(3):442-6. doi: 10.1007/s11095-009-0026-9. Epub 2010 Feb 5. Pharm Res. 2010. PMID: 20135207

9

Prediction of human blood-to-plasma drug concentration ratio.

Uchimura T, Kato M, Saito T, Kinoshita H. Uchimura T, et al. Among authors: kato m. Biopharm Drug Dispos. 2010 Jul;31(5-6):286-97. doi: 10.1002/bdd.711. Biopharm Drug Dispos. 2010. PMID: 20549836

10

Estimation of the interindividual variability of cytochrome 2D6 activity from urinary metabolic ratios in the literature.

Ito T, Kato M, Chiba K, Okazaki O, Sugiyama Y. Ito T, et al. Among authors: kato m. Drug Metab Pharmacokinet. 2010;25(3):243-53. doi: 10.2133/dmpk.25.243. Drug Metab Pharmacokinet. 2010. PMID: 20610883

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results